Benefits and adverse effects of anti-emetic glucocorticoids in cancer

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 921-922

  Brüning, Ansgar ^a   Friese, Klaus ^a   Runnebaum, Ingo B ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

5 HT3 receptor; Apoptosis; Chemotherapy; Dexamethasone; Emesis

Indexed keywords

ANTIEMETIC AGENT; ARACHIDONIC ACID; CASPASE 9; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; CYTOSTATIC AGENT; DEXAMETHASONE; GLUCOCORTICOID; METALLOTHIONEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONDANSETRON; PLATINUM COMPLEX; PROSTAGLANDIN E2; PROTEIN BAD; PROTEIN SERINE THREONINE KINASE; SEROTONIN; SEROTONIN 3 RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; DRUG EFFICACY; ENTEROCHROMAFFIN CELL; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; IN VITRO STUDY; INTESTINE MUCOSA; MUCOSA CELL; NAUSEA AND VOMITING; NONHUMAN; NOTE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; VAGUS NERVE;

EID: 33751182883     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.3313     Document Type: Note

References (24)

1. Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 2003; 99:149-65.
2. Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:97-103.
3. Olver IN. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J 2005; 35:478-81.
4. Smith DB, Newlands ES, Rustin GJ, Begent RH, Howells N, McQuade B, Bagshawe KD. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338:487-90.
5. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12:596-600.
6. Suzuki T, Sugimoto M, Koyama H, Mashimo T, Uchida I. Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology 2004; 101:660-5.
7. Newton R, Seybold J, Kuitert LM, Bergmann M, Barnes PJ. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 1998; 273:32312-21.
8. Chang TC, Hung MW, Jiang SY, Chu JT, Chu LL, Tsai LC. Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett 1997; 415:11-5.
9. Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 1998; 17:1567-75.
10. Mariotta M, Perewusnyk G, Koechli OR, et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol 1999; 175:392-6
11. Herr I, Ucur E, Herzer K, et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63:3112-20.
12. Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2006; 119:712-7.
13. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis. Cancer Biol Ther 2006; This issue
14. Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J, Herr I. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 2005; 92:1084-8.
15. Gascoyne DM, Krypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem 2003; 278:18022-9.
16. Webster JC, Huber RM, Hanson RL, et al. Dexamethasone and tumor necrosis factor act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002; 143:3866-74.
17. Runnebaum IB, Bruning A. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 2005; 11:6325-32.
18. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276:16649-54.
19. Wu W, Chaudhuri S, Brickley DR, et al. Microarray analysis reveals glucocorticoidregulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64:1757-64.
20. Karin M, Herschman HR. Dexamethasone stimulation of metallothionein synthesis in HeLa cell cultures. Science 1979; 204:176-7.
21. Meyer S, Eden T, Kalirai H. Dexamethasone Protects Against Cisplatin-Induced Activation of the Mitochondrial Apoptotic Pathway in Human Osteosarcoma Cells. Cancer Biol Ther 2006; This isssue
22. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115:2618-24.
23. Sasson R, Shinder V, Dantes A, Land A, Amsterdam A. Activation of multiple signal transduction pathways by glucocorticoids: protection of ovarian follicular cells against apoptosis. Biochem Biophys Res Commun 2003;311: 1047-56.
24. Sionov RV, Cohen O, Kfir S, Zilberman Y, Yefenof E. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med 2006; 203:189-201.